Benzinga··Globe NewswireMerck to Acquire Terns Pharmaceuticals for $6.7B to Bolster CML Portfolio
Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.
MRKTERNacquisitionM&A
chronic myeloid leukemia
2 articlesBenzinga··Globe Newswire
Benzinga··Tanya RawatMerck to Acquire Terns Pharma for $6B, Bolstering Oncology Pipeline Before Keytruda Patent Cliff
Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.
MRKNVSTERNacquisitionM&A